Form 4: Catalyst Pharma Officer's Stock Vesting and Tax Withholding

Catalyst Pharmaceuticals' Chief Compliance/Legal Officer, Brian Elsbernd, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Summary

• Brian Elsbernd, Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported transactions on December 29, 2025.
• Acquired 6,667 shares of common stock through the vesting of restricted stock units (RSUs).
• Disposed of 2,623 shares of common stock to satisfy applicable withholding taxes upon the vesting of restricted common stock.
• Beneficial ownership of common stock following these transactions is 242,501 shares.
• The reported restricted stock units vested in three equal tranches on December 27, 2023, December 27, 2024, and December 27, 2025.
• The final tranche of shares was delivered to the reporting person on December 29, 2025.
• Remaining derivative securities (Restricted Stock Units) beneficially owned are 956,142.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The vesting of RSUs is a positive for the officer and indicates ongoing compensation, while the tax withholding is a routine, neutral event. This filing does not signal any major operational or financial news.

Positives

• The vesting of restricted stock units represents a standard component of long-term incentive compensation for a key officer, aligning management interests with shareholders.
• The officer continues to hold a significant number of common shares (242,501) and derivative securities (956,142 RSUs), demonstrating continued equity alignment with the company's performance.

Negatives

• The disposition of 2,623 shares for tax withholding reduces the officer's direct shareholding, although this is a routine and expected practice for RSU vesting.

Stakeholder Impact

• Shareholders: Minor dilution from RSU issuance (already accounted for in compensation plans), but also alignment of officer's interests with shareholders through continued stock ownership.
• Employees: Reflects standard executive compensation practices within the company.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and subsequent tax-related share disposition by a Chief Compliance/Legal Officer. Such transactions are standard components of executive compensation and do not typically indicate a change in the company's fundamental outlook or operational performance. The officer continues to hold a substantial number of shares and derivative securities, maintaining alignment with shareholder interests. Therefore, this filing alone does not warrant a change in investment recommendation, suggesting a 'hold' position based solely on this information.

Keywords

Catalyst Pharmaceuticals, CPRX, Form 4, Insider Transaction, Stock Vesting, Restricted Stock Units, Officer Compensation, Brian Elsbernd, Share Ownership